Clinical Trials Logo

Insulin Resistance clinical trials

View clinical trials related to Insulin Resistance.

Filter by:

NCT ID: NCT00129792 Completed - Obesity Clinical Trials

Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome

Start date: January 2005
Phase: N/A
Study type: Interventional

This study will determine the effects of a supplement in reducing symptoms of metabolic syndrome, a collection of symptoms that increase the risk for developing heart disease, stroke, and diabetes.

NCT ID: NCT00128154 Completed - Obesity Clinical Trials

Chromium Picolinate for the Treatment of Metabolic Syndrome

Start date: January 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether chromium supplements can reduce symptoms of metabolic syndrome, a collection of symptoms that increase one's risk for developing heart disease, stroke, and diabetes.

NCT ID: NCT00125853 Completed - Hypertension Clinical Trials

The Effect of Nebivolol on Insulin Sensitivity

Start date: July 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to conduct a randomised trial to compare the insulin sensitivity, 24 hour blood pressure profile, and tolerability of nebivolol plus a thiazide-like diuretic versus atenolol plus a thiazide-like diuretic.

NCT ID: NCT00123110 Completed - Insulin Resistance Clinical Trials

Insulin Resistance and Testosterone in Women

Start date: July 2005
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine if a relationship between insulin resistance (IR) and testosterone (T) exists in women who have already gone through menopause.

NCT ID: NCT00121875 Terminated - Turner Syndrome Clinical Trials

Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature

Start date: June 2005
Phase: Phase 4
Study type: Observational

Growth hormone treatment improves body fat distribution but also causes insulin resistance. Scientists have recently linked insulin resistance with special stores of fat in the muscles, which can be measured by magnetic resonance imaging (MRI). The researchers hypothesize that growth hormone will paradoxically reverse the linkage between muscle fat stores and insulin resistance. To assess this association and to investigate the cause(s), the researchers will measure muscle fat stores during growth hormone treatment. Other parameters linked to insulin resistance (glucose tolerance, blood markers, and body composition) will also be assessed. This study may lead to improved strategies for monitoring growth hormone therapy.

NCT ID: NCT00120497 Recruiting - Clinical trials for Fetal Growth Retardation

Study to Examine Insulin Resistance During Growth Hormone Treatment for Short Stature Due to Low Birthweight

Start date: July 2005
Phase: Phase 4
Study type: Observational

Insulin resistance is common among children with low birthweight. Moreover, growth hormone treatment for ensuing short stature also causes insulin resistance. Our objective is to examine these processes. Insulin resistance has recently been linked to the accumulation of stores of fat in muscle cells which can be measured by MRI. We hypothesize that children who are short due to low birthweight have increased muscle fat stores, but that growth hormone treatment will paradoxically reverse this association. To test this hypothesis, muscle fat stores will be measured in children who are short due to low birthweight before and after receiving growth hormone therapy. Other parameters linked to insulin resistance (glucose tolerance, blood markers, and body composition) will also be assessed. This study may lead to ways to increase growth hormone safety and dose limitations.

NCT ID: NCT00109746 Completed - HIV Infections Clinical Trials

Use of a Nutritional Supplement to Treat Diabetic Symptoms in HIV-Infected Adults

NT
Start date: November 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness of the nutritional supplement chromium picolinate in improving insulin resistance, a symptom of diabetes, in HIV-infected patients. The ultimate goal is to find a simple therapy that can prevent the development of diabetes in individuals with HIV.

NCT ID: NCT00099697 Completed - Obesity Clinical Trials

Biologic Effects of Dehydroepiandrosterone (DHEA) in Humans

Start date: June 2001
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether DHEA replacement therapy decreases abdominal fat and improves insulin sensitivity.

NCT ID: NCT00099476 Completed - Hypertension Clinical Trials

Effects of Dark Chocolate on Insulin Sensitivity in People With High Blood Pressure

Start date: December 10, 2004
Phase: Phase 1
Study type: Interventional

This study will examine whether dark chocolate affects the way patients with hypertension (high blood pressure) respond to insulin, a hormone secreted by the pancreas that regulates blood glucose (sugar) levels. In many people with hypertension, insulin is not as effective in helping the body use glucose. This is called insulin resistance. Insulin also increases blood flow into muscle by opening inactive blood vessels. Laboratory studies suggest that eating dark chocolate may improve blood pressure. This study will determine whether dark chocolate improves insulin resistance or changes how blood vessels react to insulin in hypertensive people. People between 21 and 65 years of age who have high blood pressure and are not pregnant may be eligible for this study. Candidates are screened with a medical history, physical examination, and blood and urine tests. Participants refrain from eating foods containing chocolate or cocoa for 1 week and then come to the clinic on three separate occasions 3 weeks apart for a glucose clamp test and contrast ultrasound, described below. At the first glucose clamp test, subjects are randomly assigned to drink either a cocoa drink with high anti-oxidant content or one with a very low content of anti-oxidant. Each drink will be taken twice a day for 2 weeks. At the end of the 2 weeks, they return for a second glucose clamp test. At the second test, they stop taking the cocoa drink for 1 week and then start again for another 2 weeks. For this 2-week period, those who were given the high anti-oxidant content cocoa drink the first 2 weeks will take the placebo, very low anti-oxidant drink this time, and those who took the placebo will now have the high anti-oxidant cocoa drink. After this 2 weeks of taking the cocoa drink or placebo, they then take the third and last glucose clamp test. Glucose clamp test: This test measures how the body responds to insulin. Subjects fast the night before each test and do not eat until the test is over, usually in the early afternoon. For the test, the subject lies in a bed or reclines in a chair. A needle is placed in a vein in each arm - one for collecting blood samples and the other for infusing glucose, insulin, and a potassium solution. Blood glucose and insulin levels are measured frequently during the test and the rate of the glucose infusion is adjusted to keep blood glucose at the baseline (fasting) level. Blood samples are tested for blood count, electrolytes, liver function...

NCT ID: NCT00096421 Completed - Critical Illness Clinical Trials

Tight Glycemic Control in Critical Care Patients

Start date: July 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the impact of tight control of serum glucose levels with an intensive insulin treatment in patients hospitalized in an intensive care unit with medical and surgical patients.